Adams C, Suescun J, Haque A, Block K, Chandra S, Ellmore T
Clin Park Relat Disord. 2023; 8:100187.
PMID: 36793590
PMC: 9922918.
DOI: 10.1016/j.prdoa.2023.100187.
Morimoto S, Takao M, Hatsuta H, Nishina Y, Komiya T, Sengoku R
PLoS One. 2017; 12(2):e0171524.
PMID: 28166276
PMC: 5293256.
DOI: 10.1371/journal.pone.0171524.
Jimenez-Jimenez F, Alonso-Navarro H, Garcia-Martin E, Agundez J
Front Cell Neurosci. 2014; 8:369.
PMID: 25426023
PMC: 4227512.
DOI: 10.3389/fncel.2014.00369.
Mann J, Stanley M, Kaplan R, Sweeney J, Neophytides A
J Neurol Neurosurg Psychiatry. 1983; 46(10):905-10.
PMID: 6644314
PMC: 1027603.
DOI: 10.1136/jnnp.46.10.905.
Godwin-Austen R
J Neurol Neurosurg Psychiatry. 1971; 34(3):219-23.
PMID: 5571307
PMC: 1083454.
DOI: 10.1136/jnnp.34.3.219.
Retarded depression and the dopamine metabolism.
Korf J, van Praag H
Psychopharmacologia. 1971; 19(2):199-203.
PMID: 5565740
DOI: 10.1007/BF00402643.
Phenolic acid concentrations in the lumbar cerebrospinal fluid of Parkinsonian patients treated with L-dopa.
Pullar I, Weddell J, Ahmed R, GILLINGHAM F
J Neurol Neurosurg Psychiatry. 1970; 33(6):851-7.
PMID: 5531904
PMC: 493603.
DOI: 10.1136/jnnp.33.6.851.
Cerebrospinal fluid choline in extrapyramidal disorders.
Aquilonius S, Nystrom B, SCHUBERTH J, Sundwall A
J Neurol Neurosurg Psychiatry. 1972; 35(5):720-5.
PMID: 4263743
PMC: 494156.
DOI: 10.1136/jnnp.35.5.720.
Use of cerebrospinal fluid drawn at pneumoencephalography in the study of monoamine metabolism in man.
Garelis E, Sourkes T
J Neurol Neurosurg Psychiatry. 1974; 37(6):704-10.
PMID: 4210686
PMC: 494750.
DOI: 10.1136/jnnp.37.6.704.
On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
Casati C, Agnoli A, JORI A, Dolfini E
Z Neurol. 1973; 204(2):149-54.
PMID: 4121468
DOI: 10.1007/BF00315939.
Approaches to the study of cerebral dopamine metabolism in certain extrapyramidal diseases.
Barkhatova V, KANDEL E, Demina E
Neurosci Behav Physiol. 1985; 15(2):132-9.
PMID: 3160969
DOI: 10.1007/BF01186980.
Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
Campanella G, Algeri S, Cerletti C, Dolfini E, JORI A, Rinaldi F
Eur J Clin Pharmacol. 1977; 11(4):255-61.
PMID: 862646
DOI: 10.1007/BF00607673.
